Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2016 · 10-Q
Revenue$9.60K$9.60K−55.6% vs Q3 2015 Net Income-$1.78M-$1.78MN/M vs Q3 2015 EPS Diluted-$0.07-$0.07N/M vs Q3 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$216,136N/M Margins · derivedGross margin-42.3%+9.6 pt vs Q3 2015
Operating margin-16203.9%−8377.5 pt vs Q3 2015
Net margin-18579.6%−10695.8 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 21, 2016 · 52 d after period end